Monthly Archives: October 2025

AB Science announces the successful completion of a 2.8 million euros private placement

17/10/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.8 million subscribed by a limited number of investors

Summary of the virtual conference held on October 16, 2025

16/10/2025 – AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

AB Science webcast of October 16, 2025

16/10/2025 – Presentation of the AB Science webcast held on October 16, 2025

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939

14/10/2025 – The purpose of this virtual conference will be to present in more detail the initial clinical data on the combination of AB8939 + venetoclax in the first three patients with refractory and relapsed AML

Revenues for the first half of 2025 and update on AB Science’s activities

10/10/2025 – AB Science today reports its revenues for the first half of 2025 and provides an update on its activities